A single pivotal adaptive trial in infants with proliferating hemangioma: Rationale, design challenges, experience and recommendations

Modern Adaptive Randomized Clinical Trials: Statistical and Practical Aspects

Volumn , Issue , 2015, Pages 453-482

  Heritier, Stephane ^a   Morgan Bouniol, Caroline C ^b   Lô, Serigne N ^c   Gautier, Stephanie ^d   Voisard, Jean Jacques ^e  

^a MONASH UNIVERSITY   (Australia)

^b Cytel Incorporated   (United States)

^c UNIVERSITY OF SYDNEY   (Australia)

^d INSTITUT DE RECHERCHE PIERRE FABRE   (France)

^e Centre d'Immunologie Pierre Fabre   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DATA MONITORING; DESIGN CHALLENGES; EARLY STOPPING; INTERIM ANALYSIS; PHASE II; SAMPLE SIZES; SYSTEMIC THERAPY; TRIAL DESIGNS;

PEDIATRICS;

EID: 85009447111     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1201/b18640     Document Type: Chapter

References (38)

1. Antonijevic, Z., Gallo, P., Chuang-Stein, C., Dragalin, V., Loewy, J., Menon, S., Miller, E. R., Morgan, C. C., Sanchez, M. (2013). Views on emerging issues pertaining to data monitoring committees for adaptive trials. Therapeutic Innovation & Regulatory Science 47, 495-502.
2. Bauer, P., Koenig, F. (2006). Mid-course sample size modification in clinical trials based on the observed treatment effect. Statistics in Medicine 25, 23-36.
3. Bauer, P., Koenig, F., Brannath, W., Posch, M. (2010). Selection and bias-Two hostile brothers. Statistics in Medicine 29(1), 1-13.
4. Bretz, F., Schmidli, H., Koenig, F., Racine, A., Maurer, W. (2006). Con-firmatory seamless phase II/III clinical trials with hypotheses selection at interim: general concepts. Biometrical Journal 48, 623-634.
5. Bretz, F., König, F., Brannath, W., Glimm, E., Posch, M. (2009). Adaptive designs for confirmatory clinical trials. Statistics in Medicine 28, 1181-1217.
6. Bretz, F., Maurer, W., Brannath, W., Posch, M. (2009). A graphical approach to sequentially rejective multiple test procedures. Statistics in Medicine 28(4), 586-604.
7. Chang, M., Chow, S. C. (2007). Analysis strategies for adaptive designs with multiple endpoints. Journal of Biopharmaceutical Statistics 17, 1189-1200.
8. CPMP Points to consider on application with 1. Meta-analyses; 2. One pivotal study-CPMP/EWP/2330/99 - 2001.
9. European Agency for the Evaluation of Medicinal Products Evaluation of Medicines for Human Use. Points to Consider on Multiplicity Issues in Clinical Trials. CPMP/EWP/908/99, 2002. London, UK.
10. EMEA (European Medicines Agency) Committee for Medicinal Products for Human Use (CHMP). Reection paper on methodological issues in confirmatory clinical trials planned with an adaptive design. (18 October 2007). http://www.emea.eu.int/pdfs/human/ewp/245902en.pdf
11. FDA (Food and Drug Administration). (2010). Guidance for Industry: Adaptive Design Clinical Trials for Drugs and Biologics (draft document).
12. Fisher, R. A. (1932). Statistical Methods for Research Workers. 4th edition. Oliver and Boyd: London.
13. Frieden, I. J., Eichenfield, L. F., Esterly, N. B., Geronemus, R., Mallory, S. B. (1997). Guidelines of care for hemangiomas of infancy. American Academy of Dermatology Guidelines/Outcomes Committee. Journal of the American Academy of Dermatology 37, 631-637.
14. Gallo, P., Chuang-Stein, C., Dragalin, V., Gaydos, B., Krams, M., Pinheiro, J. (2006). Adaptive design in clinical drug development an executive summary of the PhRMA Working Group (with discussion). Journal of Biopharmaceutical Statistics 16, 275-283.
15. Gaydos, B., Anderson, K. M., Berry, D., Burnham, N., Chuang-Stein, C., Dudinak, J., Fardipour, P., Gallo, P., Givens, S., Lewis, R., Maca, J., Pinheiro, J., Pritchett, Y., Krams, M. (2009). Good practices for adaptive clinical trials in pharmaceutical product development. Drug Information Journal 43, 539-556.
16. Léauté-Labréze, C., Hoeger, P., Mazereeuw-Hautier, J., Guibaud, L., Baselga, E., Posiunas, G., Phillips, R. G., Caceres, H., Lopez Guttierez, J. C., Ballona, R., Friedlander, S. F., Powel, J., Perek, D., Metz, B., Barbarot, S., Maruani, A., Szalai, Z. Z., Krol, A., Boccara, O., Mancini, A. J., Vabres, P., Souteyrand, P., Frieden, I. J., Berul, C. I., Mehta, C. R., Frey, S., Borallevi, F., Morgan, C. C., Heritier, S., Delarue, A., Voisard, J. J. (2015). A randomized controlled trial of oral propranolol in infantile hemangioma. The New England Journal of Medicine 372, 735-746.
17. Heritier, S., Lô, S., Morgan, C. C. (2011). An adaptive confirmatory trial with interim treatment selection: Practical experiences and unbalanced randomization. Statistics in Medicine 30, 1541-1554.
18. Hochberg, Y., Tamhane, A. C. (1987). Multiple Comparison Procedures. Wiley: New York.
19. Hoornweg, M. J., Smeudlers, M. J., van der Horst, C. M. (2005). Prevalence and characteristics of hemangiomas in young children. Nederlands tijdschrift voor geneeskunde 149, 2455-2458.
20. Irle, S., Schäfer, H. (2012). Interim design modifications in time-to-event studies. Journal of the American Statistical Association 107(497), 341-348.
21. Jenkins, M., Stone, A., Jennison, C. (2011). An adaptive seamless phase II/III design for oncology trials with subpopulation selection using correlated survival endpoints. Pharmaceutical Statistics 10(4), 347-356.
22. Jennison, C., Turnbull, B. W. (2003). Mid-course sample size modification in clinical trials based on the observed treatment effect. Statistics in Medicine 22, 971-993.
23. Jennison, C., Turnbull, B. W. (2007). Adaptive seamless designs: Selection and prospective testing of hypotheses. Journal of Biopharmaceutical Statistics 17, 1135-1161.
24. Kilcline, C., Frieden, I. J. (2008). Infantile hemangiomas: How common are they? A systematic review of the medical literature. Pediatric Dermatology 25, 168-173.
25. Klinglmueller, F., Posch, M., Koenig, F. (2014). Adaptive graph-based multiple testing procedures. Pharmaceutical Statistics 13, 345-356.
26. Lawrence, D., Bretz, F., Pocock, S. (2014). INHANCE: An adaptive con-firmatory study with dose selection at interim. In Trifilieff, A., editor; Parnham, M. J. and Bruinvels, J., series editors, Milestones in Drug Therapy, Springer.
27. Marcus, R., Peritz, E., Gabriel, K. R. (1976). On closed testing procedures with special reference to ordered analysis of variance. Biometrika 63, 655-660.
28. Mehta, C. R., Pocock, S. J. (2011). Adaptive increase in sample size when interim results are promising: A practical guide with examples. Statistics in Medicine 20(28), 3267-3284.
29. Morgan, C. C., Huyck, S., Jenkins, M., Chen, L., Bedding, A., Coffey, C. S., Gaydos, B., Wathen, J. K. (2014). Adaptive design: Results of 2012 survey on perception and use. Therapeutic Innovation & Regulatory Science 48, 473-481.
30. Munden, A., Butschek, R., Tom, W., et al. (2014). Prospective study of infantile hemangiomas: Incidence, clinical characteristics, and association with placental anomalies. British Journal of Dermatology 170, 907-913.
31. Posch, M., Bauer, P., Brannath, W. (2013). Issues in designing exible trials. Statistics in Medicine 23, 953-969.
32. Posch, M., Koenig, F., Branson, M., Brannath, W., Dunger-Baldauf, C., Bauer, P. (2005). Testing and estimation in exible group sequential designs with adaptive treatment selection. Statistics in Medicine 24, 3697-3714.
33. Proschan, M. A., Hunsberger, S. A. (1995). Designed extension of studies based on conditional power. Biometrics 51, 1315-1324.
34. Rosenkranz, G. K. (2014). Bootstrap corrections of treatment effect estimates following selection. Computational Statistics and Data Analysis 69, 220-227.
35. Schmidli, H., Bretz, F., Koenig, F., Racine, A., Maurer, W. (2006). Con-firmatory seamless phase II/III clinical trials with hypotheses selection at interim: Applications and practical considerations. Biometrical Journal 48, 635-643.
36. Simes, R. J. (1986). An improved Bonferroni procedure for multiple tests of significance. Biometrika 73, 751-754.
37. Snapinn, S., Chen, M.G., Jiang, Q., Koutsoukos, K. (2006). Assessment of futility in clinical trials. Pharmaceutical Statistics 5, 273-281.
38. Turnbull, B. W., Jennison, C. (2009). Comparison efficiency for adaptive and non-adaptive group sequential trials. In Proceedings of the 57th Session of the International Statistical Institute, Durban, South Africa.